TPST / Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals

Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the more_horizontal

Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nea more_horizontal

Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock' more_horizontal

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard- more_horizontal

Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ: TPST ). This little-known clinical-stage oncology company has gone from trading a more_horizontal

Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer therapies more_horizontal

Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigatio more_horizontal

Tempest Therapeutics (NASDAQ: TPST ) stock is taking off on Wednesday as the clinical-stage oncology company prepares to release new study results. A more_horizontal